AUA 2025: Prognostic Impact of the Maximal Evaluable Lesion Size in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab Combination Therapy
AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Maximal Evaluable Lesion Size in Patients with Metastatic Renal Cell Carcinoma, Nivolumab plus Ipilimumab Combination Therapy, nivolumab, ipilimumab, nivolumab plus ipilimumab.